{"generic":"Ethiodized Oil","drugs":["Ethiodized Oil","Ethiodol"],"mono":[{"id":"215830-s-0","title":"Generic Names","mono":"Ethiodized Oil"},{"id":"215830-s-1","title":"Dosing and Indications","sub":{"0":{"id":"215830-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Hysterosalpingography:<\/b> increments of 2 mL INTRA-ENDOMETRIAL INJECTION until tubal patency determined<\/li><li><b>Imaging of liver:<\/b> 1.5 to 15 mL via slow INTRA-ARTERIAL INJECTION with continuous radiologic monitoring; MAX, 20 mL<\/li><li><b>Lymphadenogram:<\/b> unilateral lymphography of upper extremities, 2 to 4 mL via INTRALYMPHATIC CHANNEL INJECTION<\/li><li><b>Lymphadenogram:<\/b> unilateral lymphography of lower extremities, 6 to 8 mL via INTRALYMPHATIC CHANNEL INJECTION<\/li><li><b>Lymphadenogram:<\/b> penile lymphography, 2 to 3 mL via INTRALYMPHATIC CHANNEL INJECTION <\/li><li><b>Lymphadenogram:<\/b> cervical lymphography of upper extremities, 1 to 2 mL via INTRALYMPHATIC CHANNEL INJECTION <\/li><\/ul>"},"1":{"id":"215830-s-1-5","title":"Pediatric Dosing","mono":"<b>Lymphadenogram:<\/b> MIN of 1 mL to MAX of 6 mL via INTRALYMPHATIC CHANNEL INJECTION, based on anatomical area for imaging; MAX 0.25 mL\/kg "},"3":{"id":"215830-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Hysterosalpingography<\/li><li>Imaging of liver<\/li><li>Lymphadenogram<\/li><\/ul>"}}},{"id":"215830-s-2","title":"Black Box Warning","mono":"<b>Injection (Oil)<\/b><br\/>Inadvertent intravascular injection or intravasation of ethiodized oil may cause pulmonary and cerebral embolism. Inject slowly with radiologic monitoring; do not exceed recommended dose.<br\/>"},{"id":"215830-s-3","title":"Contraindications\/Warnings","sub":[{"id":"215830-s-3-9","title":"Contraindications","mono":"<ul><li>hypersensitivity to ethiodized oil<\/li><li>hyperthyroidism<\/li><li>recent bleeding or hemorrhage<\/li><li>trauma<\/li><li>Hepatocellular Carcinoma, Selected Hepatic Intraarterial Use:<\/li><li>-- areas of bile duct dilation without pretreatment external biliary drainage<\/li><li>Hysterosalpingography:<\/li><li>-- acute pelvic inflammatory disease<\/li><li>-- endocervicitis and intrauterine bleeding<\/li><li>-- phase immediately before or after menstruation<\/li><li>-- interval within 30 days of curettage or conization<\/li><li>-- marked cervical erosion<\/li><li>-- pregnancy<\/li><li>Lymphography:<\/li><li>-- advanced neoplastic disease with expected lymphatic obstruction<\/li><li>-- advanced pulmonary disease<\/li><li>-- previous surgery that causes lymphatic system interruption<\/li><li>-- radiation therapy to the examined area<\/li><li>-- right to left cardiac shunt<\/li><li>-- tissue trauma or hemorrhage<\/li><\/ul>"},{"id":"215830-s-3-10","title":"Precautions","mono":"<ul><li>Black Box Warning:<\/li><li>-- pulmonary and cerebral embolism can occur with inadvertent intravascular injection or intravasation; monitoring recommended<\/li><li>Endocrine:<\/li><li>-- hyperthyroidism or hypothyroidism may occur, with increased risk in patients with latent hyperthyroidism, Hashimoto thyroiditis, or history of thyroid irradiation<\/li><li>Hepatic:<\/li><li>-- life-threatening and fatal hepatic vein thrombosis and liver insufficiency have been reported<\/li><li>-- hepatic intraarterial administration may worsen portal hypertension or hepatic ischemia and induce fever, abdominal pain, variceal bleeds, liver enzyme elevations, ascites, encephalopathy, or hepatic failure<\/li><li>-- increased risk of vascular complications and infections with hepatic intraarterial administration<\/li><li>Immunologic:<\/li><li>-- life-threatening anaphylactoid and anaphylactic reactions have rarely occurred; monitoring recommended; avoid use in patients with a history of sensitivity to iodinated contrast agents, bronchial asthma, or allergic disorders<\/li><li>Neurologic:<\/li><li>-- cerebral embolism has been reported with inadvertent intravascular injection or intravasation; monitoring recommended; avoid use in patients with severe lung function impairment, cardiorespiratory failure, or right-sided cardiac overload<\/li><li>Respiratory:<\/li><li>-- pulmonary embolism has been reported with intravascular injection or intravasation, which may progress to life-threatening respiratory complications; monitoring recommended; avoid use in patients with severe lung function impairment, cardiorespiratory failure, or right-sided cardiac overload<\/li><\/ul>"},{"id":"215830-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"215830-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},{"id":"215830-s-4","title":"Drug Interactions","sub":[{"id":"215830-s-4-13","title":"Contraindicated","mono":"<ul>Metformin (theoretical)<\/ul>"}]},{"id":"215830-s-5","title":"Adverse Effects","mono":"<b>Serious<\/b><ul><li><b>Hepatic:<\/b>Hepatic vein thrombosis, Liver failure<\/li><li><b>Immunologic:<\/b>Anaphylactoid reaction, Hypersensitivity reaction<\/li><li><b>Neurologic:<\/b>Cerebral embolism<\/li><li><b>Respiratory:<\/b>Pulmonary embolism<\/li><\/ul>"},{"id":"215830-s-6","title":"Drug Name Info","sub":{"0":{"id":"215830-s-6-17","title":"US Trade Names","mono":"Ethiodol<br\/>"},"2":{"id":"215830-s-6-19","title":"Class","mono":"Radiological Non-Ionic Contrast Media<br\/>"},"3":{"id":"215830-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}}},{"id":"215830-s-7","title":"Mechanism Of Action","mono":"Ethiodized oil is an iodinated oil-based imaging agent that is distributed in the liver and remains for 2 to 4 weeks in healthy subjects and longer in patients with hepatocellular carcinoma, allowing for imaging and re-imaging weeks after administration.<br\/>"},{"id":"215830-s-8","title":"Pharmacokinetics","sub":{"1":{"id":"215830-s-8-24","title":"Distribution","mono":"hepatic parenchyma: extensive <br\/>"},"2":{"id":"215830-s-8-25","title":"Metabolism","mono":"Liver: phagocytized <br\/>"},"3":{"id":"215830-s-8-26","title":"Excretion","mono":"Hepatic lymph system: extensive <br\/>"},"4":{"id":"215830-s-8-27","title":"Elimination Half Life","mono":"5.2 to 12.6 days <br\/>"}}},{"id":"215830-s-9","title":"Administration","mono":"<b>Injection<\/b><br\/><ul><li>use glass syringe for administration and use promptly<\/li><li>discard unused drug<\/li><li>hepatic intra-arterial injection: administer slowly with continuous radiologic monitoring; discontinue with evidence of stagnation or reflux<\/li><li>lymphography: use frequent radiologic monitoring to assess administration rate and follow lymphatic progression<\/li><li>lymphography: inject no faster than 0.2 mL\/min, but inject total dose over of minimum of 1.25 hours<\/li><li>lymphography: interrupt administration if patient has pain; discontinue administration if ethiodized oil is observed in thoracic duct or with lymphatic blockage<\/li><\/ul>"},{"id":"215830-s-10","title":"Monitoring","mono":"<ul><li>adequate visualization of hysterosalpingography, lymphography, or hepatocellular carcinoma tumors indicate efficacy<\/li><li>renal dysfunction; in all patients prior to intraarterial administration<\/li><li>renal function; consider followup assessment in patients with history of renal dysfunction<\/li><\/ul>"}]}